European journal of medicinal chemistry

PloS one

Bioorganic & medicinal chemistry letters

Carbohydrate polymers

current drug discovery technologies

drug discoveries & therapeutics

Biomacromolecules

Trials

ophthalmology

excli journal

the journal of sports medicine and physical fitness

Antiviral research

the journal of general virology

Medical gas research

[1] Cinnamamide: An insight into the pharmacological advances and structure-activity relationships.

[2] Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307.

[3] Polyphosphonium-oligochitosans decorated with nanosilver as new prospective inhibitors for common human enteric viruses.

[4] The effect of short period high intensity circuit training modified- FIFA 11+ program on physical fitness among young football players.

[5] Linkage disequilibrium and haplotype block patterns in popcorn populations.

[6] Ozone and oxidation therapies as a solution to the emerging crisis in infectious disease management: a review of current knowledge and experience.

[7] Discovery of a novel unsymmetrical structural class of HCV NS5A inhibitors with low picomolar antiviral activity.

[8] Prescribing Patterns and Costs Associated with Postoperative Eye Drop Use in Medicare Beneficiaries Undergoing Cataract Surgery.

[9] Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus.

[10] Cold atmospheric plasma as antiviral therapy - effect on human herpes simplex virus type 1.

[11] In silico structure-based design and synthesis of novel anti-RSV compounds.

[12] Treatment of SARS-CoV-2: How far have we reached?

[13] The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.

[14] understanding viral dsrna-mediated innate immune responses at the cellular level using a rainbow trout model

[15] host cell factors as antiviral targets in arenavirus infection

[16] dual acting neuraminidase inhibitors open new opportunities to disrupt the lethal synergism between streptococcus pneumoniae and influenza virus

[17] virus infection triggers mavs polymers of distinct molecular weight

[18] kshv targeted therapy: an update on inhibitors of viral lytic replication

[19] a better antiviral efficacy found in nucleos(t)ide analog (na) combinations with interferon therapy than na monotherapy for hbeag positive chronic hepatitis b: a meta-analysis

[20] avances y limitaciones en el uso de los dsrna como estrategias de control y prevención de enfermedades virales en sistemas acuícolas

[21] a novel small rna regulates tolerance and virulence in shigella flexneri by responding to acidic environmental changes

[22] balticolid: a new 12-membered macrolide with antiviral activity from an ascomycetous fungus of marine origin

[23] replication and inhibitors of enteroviruses and parechoviruses

[24] in vitro inhibition of the bovine viral diarrhoea virus by the essential oil of ocimum basilicum (basil) and monoterpenes

[25] gamma interferon: from antimicrobial activity to immune regulation

[26] Positional Isomers of Monopegylated Interferon α-2a: Isolation, Characterization, and Biological Activity

[27] A new antiviral flavone glycoside from vernonia cinerea less

[28] Novel Pyrazole-Hydrazone Derivatives Containing an Isoxazole Moiety: Design, Synthesis, and Antiviral Activity

[29] Antiviral Efficacy of Flavonoids against Enterovirus 71 Infection in Vitro and in Newborn Mice.

[30] Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

[31] Antiviral and immunomodulatory effects of polyphenols on macrophages infected with dengue virus serotypes 2 and 3 enhanced or not with antibodies

[32] Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

[33] Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

[34] Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

[35] Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017

[36] Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

[37] Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

[38] Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus

[39] New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

[40] Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

[41] Antiviral and immunomodulatory effects of polyphenols on macrophages infected with dengue virus serotypes 2 and 3 enhanced or not with antibodies

[42] Viral dynamics among HCV infected patients with different genotypes treated with genotypic specific or pan-genotypic direct-acting antiviral agent combinations

[43] Antiviral and immunomodulatory effects of polyphenols on macrophages infected with dengue virus serotypes 2 and 3 enhanced or not with antibodies

[44] Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

[45] Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

[46] Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

[47] Antiviral resistance markers in influenza virus sequences in Mexico, 2000–2017

[48] Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

[49] Pegylated-interferon plus ribavirin treatment does not alter the prevalence of resistance-associated substitutions to direct-acting antivirals in HCV genotype 1a patients

[50] Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus

[51] New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

[52] Patient characteristics and analgesic efficacy of antiviral therapy in postherpetic neuralgia.

[53] What is the optimal timing of antiviral treatment in pregnant hepatitis B carrier with extremely high viral load?

[54] Inoculation of specific pathogen-free chickens with an infectious bursal disease virus of the ITA genotype (G6) leads to a high and persistent viral load in lymphoid tissues and to a delayed antiviral response

[55] Factors affecting the purpose suppressive antiviral therapy for patients with recurrent genital herpes

[56] Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Application to assay of dosage forms and dissolution studies

[57] Discovery of novel natural flavonoids as potent antiviral candidates against hepatitis C virus NS5B polymerase.

[58] The pipeline of antiviral T-cell therapy: what's in the clinic and undergoing development.

[59] Physicochemical Properties Govern the Activity of Potent Antiviral Flavones.

[60] hnRNPA2B1: a nuclear DNA sensor in antiviral immunity.

[61] [Research on substances with antiviral activity. Carbamoyl-oxyimino derivatives of isatine and analogous heterocyclic compounds].

[62] Broad-Spectrum Antiviral Activity of an Ankyrin Repeat Protein on Viral Assembly against Chimeric NL4-3 Viruses Carrying Gag/PR Derived from Circulating Strains among Northern Thai Patients

[63] Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.

[64] Validated spectrophotometric and chromatographic methods for analysis of the recently approved hepatitis C antiviral combination ledipasvir and sofosbuvir.

[65] The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: a decision-analytic approach.

[66] Investigation of Brassica juncea, Forsythia suspensa, and Inula britannica: Phytochemical properties, antiviral effects, and safety

[67] Synthesis and antibacterial and antiviral activities of myricetin derivatives containing a 1,2,4-triazole Schiff base

[68] Antiviral activity of itraconazole against type I feline coronavirus infection.

[69] Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae).

[70] Pharmacological activities of Triazole analogues as antibacterial, antifungal, antiviral agents

[71] Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.

[72] Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease.

[73] Cryo-EM structure of pleconaril-resistant rhinovirus-B5 complexed to the antiviral OBR-5-340 reveals unexpected binding site.

[74] Cycloartane triterpenoids from Pseudolarix amabilis and their antiviral activity.

[75] Discovery of a novel unsymmetrical structural class of HCV NS5A inhibitors with low picomolar antiviral activity.

[76] Antiviral Effectors and Gene Drive Strategies for Mosquito Population Suppression or Replacement to Mitigate Arbovirus Transmission by .

[77] Comparison of broad-spectrum antiviral activities of the synthetic rocaglate CR-31-B (-) and the eIF4A-inhibitor Silvestrol.

[78] Design and synthesis of novel Imidazo[2,1-b]thiazole derivatives as potent antiviral and antimycobacterial agents.

[79] Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus.

[80] Synthesis and evaluation of some new 1,3,4-oxadiazoles bearing thiophene, thiazole, coumarin, pyridine and pyridazine derivatives as antiviral agents.

[81] Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum.

[82] Antiviral activity of extracted fraction from camel urine against corona and influenza a (H1N1) viruses

[83] Antiviral Innate Immune Response Interferes with the Formation of Replication-Associated Membrane Structures Induced by a Positive-Strand RNA Virus

[84] Cold atmospheric plasma as antiviral therapy - effect on human herpes simplex virus type 1.

[85] HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?

[86] Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia.

[87] Preclinical optimization of gp120 entry-antagonists as anti-HIV-1 agents with improved cytotoxicity and ADME properties through rational design, synthesis, and antiviral evaluation.

[88] Antiviral Effect of Epigallocatechin Gallate via Impairing Porcine Circovirus Type 2 Attachment to Host Cell Receptor.

[89] Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.

[90] Enzyme-Catalyzed Kinetic Resolution of Chiral Precursors to Antiviral Prodrugs.

[91] Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.

[92] Structure-based stabilization of non-native protein-protein interactions of coronavirus nucleocapsid proteins in antiviral drug design

[93] De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery

[94] Emetine, Ipecac, Ipecac Alkaloids and Analogues as Potential Antiviral Agents for Coronaviruses

[95] Extreme genomic CpG deficiency in SARS-CoV-2 and evasion of host antiviral defense.

[96] Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19.

[97] SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.

[98] Effects of infectious bursal disease virus infection on interferon and antiviral gene expression in layer chicken bursa

[99] Antiviral Activity of Tannic Acid Modified Silver Nanoparticles: Potential to Activate Immune Response in Herpes Genitalis.

[100] Cytomegalovirus antivirals and development of improved animal models

[101] Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study